Wang Kai, Chen Zhen, Wu Rongzu, Yin Jun, Fan Min, Xu Xianlin
Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Department of Urology, Sir Run Run Shaw Hospital, The Third Affiliated Hospital of Nanjing Medical University, Jiangning District, Nanjing, China.
Cell Physiol Biochem. 2018;45(3):993-1002. doi: 10.1159/000487294. Epub 2018 Feb 5.
BACKGROUND/AIMS: Recently, many studies have demonstrated that galectin-9 (Gal-9) exhibits altered expression and has a close association with metastasis and recurrence in various cancers. Therefore, we conducted a meta-analysis to assess the prognostic role of Gal-9 expression in solid tumours.
We searched PubMed, Embase, and Web of Science until June 2017 and identified fourteen eligible studies containing 2,408 patients to include in the meta-analysis.
The pooled results indicated that higher Gal-9 expression in cancer tissue associated with an improved CSS (HR=0.48, 95% CI 0.39-0.58). In the subgroup analysis, a significant relationship was observed between higher Gal-9 expression and both CSS (HR=0.48, 95% CI 0.39-0.59) and OS (HR=0.62, 95% CI 0.49-0.78) in digestive cancers.
The findings of this meta-analysis highlight the role of Gal-9 as a useful clinical prognostic biomarker, which may facilitate the treatment of patients with solid tumours.
背景/目的：最近，许多研究表明，半乳糖凝集素-9（Gal-9）的表达发生改变，且与多种癌症的转移和复发密切相关。因此，我们进行了一项荟萃分析，以评估Gal-9表达在实体瘤中的预后作用。
我们检索了截至2017年6月的PubMed、Embase和Web of Science数据库，确定了14项符合条件的研究，共纳入2408例患者进行荟萃分析。
汇总结果表明，癌组织中较高的Gal-9表达与较好的癌症特异性生存（CSS）相关（风险比[HR]=0.48，95%置信区间[CI] 0.39-0.58）。在亚组分析中，在消化系统癌症中观察到较高的Gal-9表达与CSS（HR=0.48，95% CI 0.39-0.59）和总生存期（OS）（HR=0.62，95% CI 0.49-0.78）均存在显著相关性。
这项荟萃分析的结果突出了Gal-9作为一种有用的临床预后生物标志物的作用，这可能有助于实体瘤患者的治疗。
